AIT Therapeutics Reports Financial Results for Three Months Ended March 31, 2018

 

Announced positive top-line data for Nitric Oxide in Bronchiolitis (NO-BRO) Pilot Study

 

Presented data from its inhaled Nitric Oxide study in patients infected with mycobacterium abscessus complex (MABSC) at the 2018 American Thoracic Society Conference

 

Strengthened IP with new patent for the Smart Filter for the nitric oxide generator and delivery system and patent allowance for delivery of inhaled nitric oxide at concentrations of at least 160ppm for treatment of bronchiolitis in infants

 

Appointed Stephen J. DiPalma as Chief Financial Officer

 

Conference Call scheduled for Thursday, June 14 at 8:30 a.m. Eastern Time

 

NEW YORK, June 14, 2018 (GLOBE NEWSWIRE) — AIT Therapeutics, Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced financial results for the fiscal fourth quarter and year ended March 31, 2018.

 

Fiscal Fourth Quarter and Recent Corporate Highlights:

 

    Announced positive top-line data from its Nitric Oxide in Bronchiolitis (NO-BRO) Pilot Study in infants demonstrating a reduction in hospital length-of-stay of 21 hours
  Presented data from its inhaled nitric oxide study in patients infected with mycobacterium abscessus complex (MABSC) at the 2018 American Thoracic Society Conference. Data demonstrated safety with no NO-related serious adverse events (SAEs) observed, as well as improvements in the 6-minute walk (6MW) test, a reduction in bacterial load, and improvements in quality-of-life and FEV 1.
  Strengthened its intellectual property portfolio for the Company’s Nitric Oxide Generator and Delivery system with a new patent grant. The patent, entitled: “Apparatus and Method for Generating Nitric Oxide in Controlled and Accurate Amounts,” covers the smart filter technology in the NO Generator and Delivery System that generates nitric oxide from room air.
    Received patent allowance for delivery of inhaled nitric oxide at concentrations of at least 160ppm for the treatment of bronchiolitis in infants. The patent, entitled: “Inhalation of Nitric Oxide for Treating Respiratory Diseases” covers use in the treatment of bacterial, viral, and/or fungal bronchiolitis in addition to the intermittent delivery of NO. The claims are covered through March 7, 2033.
  Named Stephen J. DiPalma as Chief Financial Officer
  Previously reported information in the quarter include the signing of the definitive, exclusive, global license for the NOGen nitric oxide generator with NitricGen and a $9.8 million equity financing

 

 
 

 

“We are very pleased with the progress the Company has made over the past several months. We have positive top-line data from our NO-BRO pilot study showing clear improvement in hospital length-of-stay in bronchiolitis patients; we presented positive data from our NO-NTM study at the 2018 ATS conference; and we strengthened our patent portfolio surrounding our nitric oxide generator and delivery system and the use of NO in treating bronchiolitis patients,” said Mr. Steven Lisi, Chairman and Chief Executive Officer. “Our team is continuing to execute the strategy which will improve the lives of patients and create value for our shareholders. We anticipate submitting a 510k application in pulmonary hypertension around calendar year-end 2018; meeting with the FDA to discuss the potential pivotal trial design in a NO-NTM study; and preparing to initiate a pivotal trial in bronchiolitis in the fourth quarter of calendar year 2019.”

 

Financial results for three months ended March 31, 2018

The Company announced a change in its Company’s fiscal year end from December 31 to March 31. The change resulted in a three-month transition period that began on January 1, 2018 and ended on March 31, 2018. The Company’s 2019 fiscal year will commence on April 1, 2018. As a result of the change, the following financial results reflect the three-month transition period ended March 31, 2018.

 

For the three months ended March 31, 2018, the Company posted net income of $1.0 million, or $0.15 per share. The Company had a $3.5 million benefit from the revaluation of warrants to purchase common stock, which is a non-cash item.

 

Research and development expenses were $1.6 million for the three months ended March 31, 2018. Expenses during the three month period were due to costs related to clinical trials.

 

General and administrative expenses were $0.8 million for the three months ended March 31, 2018.

 

Financial income for the three months ended March 31, 2018 was $3.5 million, primarily due to the revaluation of the warrants to purchase common stock.

 

As of March 31, 2018, the Company had cash and short-term deposits of $9.0 million. This cash balance reflects a financing in the quarter that resulted in gross proceeds of $9.8 million.

 

Conference Call & Webcast Information

 

Thursday, June 14th @ 8:30am Eastern Time

 

Domestic:   866-575-6539
International:   323-794-2423
Passcode:   1819673
Webcast:   http://public.viavid.com/index.php?id=130045

 

Replays available through June 28th:

 

Domestic:   844-512-2921
International:   412-317-6671
Conference ID:   1819673

 

 
 

 

About Nitric Oxide (NO)

Nitric oxide (NO) is a powerful molecule proven to play a critical role in a broad array of biological functions. In the airways, NO is believed to play a key role in the innate immune system at concentrations of approximately 200 ppm. In vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, both gram-positive and gram-negative, but also against other diverse organisms including mycobacteria, fungi, yeast and parasites, and has the potential to eliminate their multi-drug resistant strains.

 

About Bronchiolitis

The majority of hospital admissions of infants with bronchiolitis are caused by respiratory syncytial virus (RSV). RSV is a common and highly transmissible virus that infects the respiratory tract of most children before their second birthday. While most infants with RSV present with minor respiratory symptoms, a small percentage develop serious lower airway infections, termed bronchiolitis, which can become life-threatening. The absence of treatment options for bronchiolitis limits the care of these sick infants to largely supportive measures. AIT’s system is designed to effectively deliver 160 ppm NO, which has been proven to eliminate bacteria, viruses, fungi and other microbes from the lungs.

 

About NTM

NTM infection is a rare and serious condition causing debilitating pulmonary disease associated with increased morbidity and mortality. NTM is an emerging public health concern worldwide because of its multi-drug antibiotic resistance. Current treatment guidelines suggest a combination of multiple antibiotics delivered continually over one to two years. These complex, expensive and invasive regimens have a poor record in the treatment of MABSC. AIT’s system is designed to effectively deliver 160 ppm NO, which has been proven to eliminate bacteria, viruses, fungi and other microbes from the lungs and may work against antibiotic resistant bacteria.

 

About PPHN

Persistent pulmonary hypertension of the newborn (PPHN) is a lethal condition and a secondary to failure of normal circulatory transition at birth. It is a syndrome characterized by elevated pulmonary vascular resistance (PVR) that causes labile hypoxemia due to decreased pulmonary blood flow and right-to-left shunting of blood. Its incidence has been reported as 1.9 per 1000 live births (0.4–6.8/1000 live births) with mortality rate ranging between 4–33%. This syndrome complicates the course of about 10% of infants with respiratory failure and remains a source of considerable morbidity and mortality. NO gas is a vasodilator and is approved in dozens of countries to improve oxygenation and reduce the need for extracorporeal membrane oxygenation (EMO) in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilator support and other appropriate agents.

 

About AIT Therapeutics Inc.

AIT Therapeutics Inc. is a clinical-stage biopharmaceutical company using nitric oxide (NO) to treat respiratory and other diseases. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that are not effectively addressed with current standards of care as well as pulmonary hypertension in various settings. AIT Therapeutics is currently advancing its revolutionary NO respiratory targeted system in clinical trials for the treatment of bronchiolitis and nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com.

 

Forward-Looking Statement

This press release contains “forward-looking statements.” Forward-looking statements include statements about our expectations, beliefs, or intentions regarding our product offerings, business, financial condition, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” “likely,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to: our approach to discover and develop novel drugs, which is unproven and may never lead to marketable products; our ability to fund and the results of further pre-clinical and clinical trials; obtaining, maintaining and protecting intellectual property utilized by our products; our ability to enforce our patents against infringers and to defend our patent portfolio against challenges from third parties; our ability to obtain additional funding to support our business activities; our dependence on third parties for development, manufacture, marketing, sales, and distribution of products; the successful development of our product candidates, all of which are in early stages of development; obtaining regulatory approval for products; competition from others using technology similar to ours and others developing products for similar uses; our dependence on collaborators; and our short operating history. We undertake no obligation to update, and we do not have a policy of updating or revising, these forward-looking statements, except as required by applicable law.

 

CONTACT

Steven Lisi, Chief Executive Officer
AIT Therapeutics, Inc.
Steve@AIT-Pharm.com

 

Bob Yedid
LifeSci Advisors, LLC
Bob@LifeSciAdvisors.com
(646) 597-6989

 

 
 

 

CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands, except share and per share data

 

   As of   As of December 31, 
   March 31, 2018   2017   2016 
             
ASSETS:               
                
CURRENT ASSETS:               
Cash and cash equivalents  $733   $1,201   $7 
Restricted cash   6    6    - 
Marketable securities   8,304    606    - 
Other accounts receivable and prepaid expenses   59    109    78 
                
Total current assets   9,102    1,922    85 
                
NON-CURRENT ASSETS:               
                
Deferred private placement costs   -    -    90 
Property and equipment, net   253    267    61 
                
Total non-current assets   253    267    151 
                
TOTAL ASSETS  $9,355   $2,189   $236 

 

CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands, except share and per share data

 

   As of
March 31, 2018
   As of
December 31, 2017
   As of
December 31, 2016
 
             
LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIENCY)               
                
CURRENT LIABILITIES:               
Bank loan  $-   $-   $39 
Trade payables   842    669    528 
Other accounts payable   1,257    694    1,093 
Loans from related parties and others   33    33    379 
                
Total current liabilities   2,132    1,396    2,039 
                
NON-CURRENT LIABILITIES:               
Liability related to warrants   5,678    9,172    - 
Convertible notes   -    -    2,895 
                
TOTAL LIABILITIES   7,810    10,568    4,934 
                
COMMITMENTS AND CONTINGENCIES               
                
SHAREHOLDERS’ EQUITY (DEFICIENCY)               
                
Common Stock, $0.0001 par value per share - 100,000,000 and 11,665,085 shares authorized at March 31, 2018, December 31, 2017 and 2016, respectively 8,397,056, 6,097,254 and 2,207,449 shares issued and outstanding at March 31, 2018, December 31, 2017 and 2016, respectively   1    1    1 
Preferred Stock, $0.0001 par value per share - 10,000,000 shares authorized at March 31, 2018, December 31, 2017 and 2016; 0 issued and outstanding shares at March 31, 2018, December 31, 2017 and 2016   -    -    - 
Accumulated other comprehensive income   (3)   2    - 
Treasury shares   (25)   (25)   - 
Additional paid- in capital   32,141    23,260    8,874 
Deficit accumulated   (30,569)   (31,617)   (13,573)
                
Total shareholders’ equity (deficiency)   1,545    (8,379)   (4,698)
                
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIENCY)  $9,355   $2,189   $236 

 

 
 

 

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

U.S. dollars in thousands, except share and per share data

 

   For the Three months Ended
March 31,
 
       (Unaudited) 
   2018   2017 
         
Operating expenses:          
Research and development expenses  $1,637   $1,439 
General and administrative expenses   803    2,121 
Costs related to aborted IPO   -    - 
           
Operating loss   2,440    3,560 
           
Financial (income) expense, net   (3,488)   2,717 
           
Loss (Income) before taxes on income   (1,048)   6,277 
           
Taxes on income   -    6 
           
Net (income) loss  $(1,048)  $6,283 
           
Net unrealized loss (gain) on available-for-sale investments   5    - 
           
Total comprehensive (income) loss  $(1,043)  $6,283 
           
Net basic earnings (loss) per share of common stock  $0.15   $(1.12)
           
Net diluted earnings (loss) per share of common stock  $0.14   $(1.12)
           
Weighted average number of shares used in computing net basic earnings (loss) per share of common stock   7,196,048    5,617,762 
           
Weighted average number of shares used in computing net diluted earnings (loss) per share of common stock   7,250,194    5,617,762 

 

 
 

 

STATEMENT OF CONSOLIDATED CASH FLOWS

U.S. dollars in thousands, except share and per share data

 

   For the three months
ended
March 31,
 
   (Audited)   (Unaudited) 
   2018   2017 
Cash flows from operating activities          
Net income (loss)  $1,048   $(6,283)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation   15    6 
Stock-based compensation related to warrants, RSs and RSUs   147    1,877 
Issuance of Common Stock to finder upon the conversion of Convertible Notes   -    18 
Amortization of beneficial conversion feature and debt issuance costs related to Convertible Notes   -    1,046 
Issuance cost related to warrants liability   -    457 
Adjustment of liability warrants   -    2,434 
Revaluation of warrants to purchase Common Stock   (3,494)   (1,308)
Imputed interest on Convertible Notes, loans from related parties and others   -    30 
Change in:          
Other accounts receivables and prepaid expenses   50    (99)
Trade payables   173    20 
Other accounts payable   313    410 
Net cash used in operating activities   (1,748)   (2,212)
           
Cash flows from investing activities          
Investment in marketable securities   (9,403)   - 
Proceeds from redemption of marketable securities   1,700    - 
Purchase of property and equipment   (1)   (25)
Purchase price that has been paid upon the reverse merger   -    (295)
Net cash (used in) provided by investing activities   (7,704)   (320)
           
Cash flows from financing activities          
Proceeds from issuance of units consisting of Common Stock and warrants, net of issuance costs   8,894    9,889 
Proceeds from loan from related parties and others   -    57 
Maturity of loan and interest from related parties and others   -    (241)
Repayment of bank loan   -    (14)
Treasury shares   -    (25)
Net cash provided by financing activities   8,734    9,666 
           
Increase (decrease) in cash, cash equivalents and restricted cash   (468)   7,134 
Cash, cash equivalents and restricted cash at beginning of year   1,207    7 
Cash, cash equivalents and restricted cash at end of year  $739   $7,141 
Supplemental disclosure of non-cash financing activities:          
Conversion of Convertible Notes into Common Stock   -   $3,955 
Issuance costs related to warrants  $250   $- 

 

 
 

 


The following information was filed by Ait Therapeutics, Inc. (AITB) on Tuesday, June 19, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Ait Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Ait Therapeutics, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account